ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Financial Statements and ExhibitsItem 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press Release titled “ARCA biopharma announces Completion of Enrollment for GENETIC-AF Phase2B Clinical Trial” dated August 16, 2017. |
ARCA biopharma, Inc. ExhibitEX-99.1 2 abio-ex991_6.htm EX-99.1 abio-ex991_6.htm Exhibit 99.1 ARCA Biopharma announces completion of enrollment for genetic-af Phase 2b clinical trial ————————————————————————————————– GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation ————————————————————————————————– ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018 Westminster,…To view the full exhibit click here
About ARCA biopharma, Inc. (NASDAQ:ABIO)
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.